FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. (“GTC”, NASDAQ: GTCB) has received $3 million as a milestone payment from Lundbeck Inc. of Deerfield, IL, a subsidiary of H. Lundbeck A/S, as a result of the approval of ATryn® (Antithrombin [Recombinant]) by the Food and Drug Administration. Lundbeck Inc. was previously known as Ovation Pharmaceuticals, Inc. prior to being acquired by H. Lundbeck A/S.
